Clinical Trials
Multi-Cancer Trials
Some clinical trials are not limited to a single cancer type. These are called multi-cancer trials, and they may include patients with different tumour types that share specific features—such as genetic mutations or biomarkers.
Learn More Cancer
For general information on cancer—including risk factors, symptoms, diagnosis, and treatment—visit the Cancer Council’s website:
General Enquiries
For general questions about trial availability, eligibility, or the referral process, please contact us using the form below. Our team will respond as soon as possible.
| Protocol Number | Cancer Type | Study Name | Intervention | Mechanism of Action | Recruitment Status | Sponsor | Clinical.Trials.gov ID | Click to Enquire |
|---|---|---|---|---|---|---|---|---|
| AWT020-001 | Multi-Cancers | A Phase 1/2, First-in-human, Open-label Study of Single-agent AWT020 in Patients With Progressive Locally Advanced or Metastatic Cancer | Immunotherapy | Anti-PD1 IL-2 BiTE. | Open - Recruiting | Anwita Biosciences | NCT06092580 | Enquire Now |
| INI-4001-101 | Multi-Cancers | An Open-label, Multiple-Ascending Dose, Two-Part Dose Ranging and Cohort Expansion Study of INI-4001 in Patients With Advanced Solid Tumours | Immunotherapy | Small molecule TLR7/8 agonist. | Open - Recruiting | Inimmune Corporation | NCT06302426 | Enquire Now |
| PTT-4256-01 | Multi-Cancers | A Modular, Open Label, Dose Finding, Phase 1/2 Clinical Trial in Patients With Solid Tumours to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of PTT-4256. | Immunotherapy | Inhibitor of the pH-sensing G-protein-coupled receptor 65 | Open - Recruiting | Pathios Therapeutics Pty Ltd | NCT06634849 | Enquire Now |
| SSGJ-709-101 | Multi-Cancers | A Phase 1 Study of SSGJ-709 in Patients With Advanced Malignant Tumors | Immunotherapy | Anti-PD-1 and anti-LAG-3 bispecific antibody | Open - Recruiting | Shenyang Sunshine Pharmaceutical Co., LTD. | NCT07016490 | Enquire Now |
| ADCE-T02-01 | Multi-Cancers | First-in-Human, Phase 1 Study of ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors | Antibody Drug Conjugate | ADC targeting a tissue factor. | Open - Recruiting | Adcendo ApS | NCT06597721 | Enquire Now |
| DM002001 | Multi-Cancers | A Study of DM002 in Patients With Advanced Solid Tumors | Antibody Drug Conjugate | ADC targeting MUC1 and HER3 | Open - Recruiting | Doma Biopharmaceutical（Suzhou）Co., Ltd. | NCT06751329 | Enquire Now |
| NXT-9216-101 | Multi-Cancers | A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors | Targeted | Small molecule inhibitor of WRN helicase activity | Open - Recruiting | Nimbus Therapeutics | NCT06898450 | Enquire Now |
| SR-8541A-001 | Multi-Cancers | A phase 1 open-label, dose-escalation, multi-center phase 1 study evaluating the safety, tolerability, and pharmacokinetics (PK) of SR-8541A administered orally as a monotherapy or in combination with an immune checkpoint inhibitor (ICI) in subjects with solid tumors. in Patients With Advanced Solid Tumors | Targeted | ENPP1 inhibitor | Open - Recruiting | Stingray Therapeutics | NCT06063681 | Enquire Now |